Physician profile
Gary E Tratt
NPI 1891874947
$1,399.35
in general payments reported to CMS, 2019-2025
20 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $171 · 2021: $189 · 2022: $195 · 2023: $122 · 2024: $245 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $256.08 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $193.44 | 2019-2022 | |
| Pfizer INC. | $166.70 | 2019-2025 | |
| Abbvie INC. | $97.14 | 2023-2024 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.00 | 2021-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $81.92 | 2019-2024 | Trintellix |
| Glaxosmithkline, LLC. | $65.56 | 2020 | |
| Lilly USA, LLC | $55.99 | 2025 | Zepbound, Mounjaro |
| Vanda Pharmaceuticals INC. | $52.26 | 2019-2021 | |
| Bausch Health US, LLC | $52.26 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $47.13 | 2024-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.49 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $40.49 | 2022-2023 | Eliquis |
| Amgen INC. | $38.10 | 2024 | Evenity, Prolia |
| Rgh Enterprises LLC | $25.55 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $21.52 | 2021 | |
| Mylan Specialty L.P. | $21.19 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.74 | 2021 | |
| Merck Sharp & Dohme LLC | $14.62 | 2019 | |
| Amarin Pharma, INC. | $14.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Tratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.